TGTX - Earnings call transcript Q3 2024

Due to licensing restrictions, you must log in to view earnings call transcripts.

Operator

Greetings, and welcome to the TG Therapeutics third quarter conference call and webcast. [Operator Instructions] as a reminder, this conference is being recorded.

It's now my pleasure to turn the call over to Jenna Bosco. Please go ahead.

Jenna Bosco

Thank you. for this thanks and everyone, joining morning. us Welcome, Jenna Bosco. I'm Officer; today And our third Executive Financial Chief Officer. to our quarter Sean me Officer; Chairman Waldman, and Commercialization XXXX Chief Weiss, the Chief Michael discuss with Power, our are financial and Adam results

before of will our an Following our update harbor overview commercialization will the give developments, of corporate turning efforts, provide Mike safe recent to results Adam to Sean a over on financial summary the our begin an and the statement, our call will share operator Q&A.

begin, to development Reform our plans including operating marketed and of I'd the Before guidance, statements of that sales we meaning products. our forward-looking anticipated future performance, Litigation Securities forward-looking like about Act we making will statements performance, be revenue Private the and financial XXXX. everyone milestones, within for projected statements expectations These remind include

forward-looking to cautions from statements that results risk can actual are these risks factors Factors be cause operations our to subject that include TG may differ in SEC various TG filings. Therapeutics that affect our that materially found indicated. those may

forward-looking be our as date. forward-looking In our upon only this should statements. disclaim made any of specifically We views or representing relied not any today update call statements views as revise as of and later represent on addition, any any to obligation

where it the Weiss, I'd available Mike is recorded that, call on be being website, for will call CEO. to conference www.tgtherapeutics.com, the rebroadcast our over This turn days. next audio for to like With XX TG's

Michael Weiss

share you quarter us for everyone, and We're the morning, results and you our excited of of Jenna, BRIUMVI execution growth joining call. another and our launch. for you, good Thank of quarterly earnings with to thank

ULTIMATE highly to evaluating progress and our the the to expectations, long-term success The MS relapsing to positive meeting individuals trial the value. BRIUMVI, belief both forms and and of remain our Phase outpace of from as focused data BRIUMVI during the continues on in BRIUMVI feedback BRIUMVI marketplace current BRIUMVI. strong annual and We the you and ENHANCE I II IIIb presented grow excited uptick for to as to well the trials ECTRIMS and continues the plans commercial future our I'm our continue strengthen shareholder share with value of and with

end commercial the execute is goal in launch of believe becoming our into full kick year-end quarterly sales. happy shortly to things Commercialization review join say quarter guidance. anti-CDXX the continued that team setting and a and Adam us net phased Chief a of extremely strong year dynamic will our Let's report of I further what million. BRIUMVI #X our share. with with update a and off into wanted I'm But were growth sales momentum the terms The Officer, of the market on commercial brief U.S. $XX.X to to XXXX, the and third Waldman, heading on provide to path continues we I'm pleased prescribed continued that plan, for toward launch effort. long-term

Annual To discuss let's recent that the at the presented of ECTRIMS Meeting. end, some data BRIUMVI

As presented I meeting. the sets we alluded to X important earlier, data during

profile of over emerging treatment continuous the year BRIUMVI new III annualized from that relapse X supported of extension follow-up relapsing usage. treatment, years remained BRIUMVI fifth of of was no BRIUMVI trials the overall forms approval core of for treatment, of importantly, treatment. as every MS. were X was open-label which X signals consistent progression. an long-term in free relapse And XX% observed, safety The with safety the rate occurring X.XX from trials, X is were years with equivalent study the X disability and to our individuals After with XX reminder, years prolonged from a And patients ULTIMATE first a Phase the data of of which,

IV we were anti-CDXX have to to approach AAN were previously, further infusion previously X we the require patient on introductory to standard to experience. X start data were continue first streamline that April we the in for in MS study, require convenience first treat ways X forms depleted the MS Currently, and stated visit we've set receiving infusions CDXXs switched without the At the our This to As relapsed tolerate in the the B-cell of weeks believe initiate ECTRIMS, would therapy, current therapy. for ENHANCE showing X-hour IV presented individuals updated dose. with therapy BRIUMVI able BRIUMVI BRIUMVI. and only all look who CDXX X-hour at used to from we to

Additionally, tolerated so well infusion we as X The data first to infusion-related ECTRIMS, reactions and a infusion XX-minute XX-minute opposed on as mild, maintenance trial. being presented, presented the still hour,was preliminary, that faster time with for from while ENHANCE completely. given dose grade of BRIUMVI at BRIUMVI a the all X data our resolved first

XX-minute with forward treated have medical RMS XX We over to BRIUMVI a presenting conference. look now future updated and with individuals data at

our is imagine, including randomized seek to trials patient into longer-term the vision journey profile. and maintain more best-in-class testing will updates a potential can BRIUMVI be label. believe hopefully, our we incorporate But these you improve to what this needed As to with highlights continually

goal, developing I'd to also further subcu like BRIUMVI. of that a to achieving remind everyone that are version And we

Accordingly, with is is that X individuals BRIUMVI of months, at-home, CDXX a up subcu us. is would subcu we IV market at-home we to offering which choose self-administered BRIUMVI majority open expect delivered how MS new believe the offered for every and opportunity that continue, an currently market the meaningful. While self-administered

from to of our BRIUMVI commencing year. goes in a an next the targeting expect subcu pivotal to update if be provide middle be study early we'll well, able by bioequivalence We XXXX. all And trial

therapy application, investigational of of treatment for The an forward, the autoimmune beyond that the shared cell year progressive is CDXX that next to front. been with Phase IND, with drug exciting end for and working hard off-the-shelf And cleared azer-cel, starting offer team FDA the targeting the new have on believe diseases. for study treatment an BRIUMVI this move has allogeneic new finally, R&D previously has new We CAR This I T U.S. early we individuals opportunity this we few may are who MS MS. progressive in individuals launching or around a a year, options. our

to supply. a gears bit. and transaction a related manufacturing little to want Switching highlight I recent

been As from great filings, and partner manufacturing at to you a be continue to be currently leaders global manufacture South recognized the have Biologics aware biologics TG. as in our we public are Samsung Korea, in who BRIUMVI may and who

time engage continues as As BRIUMVI, a BRIUMVI. risk believe to manufacturer of of BRIUMVI felt we secondary to from to a we grow, continue potential the standpoint, it was management blockbuster

United happy based are at announce the here BRIUMVI in have their of we Accordingly, secured we FUJIFILM to manufacturer facility Biotechnologies second Diosynth a States. as

we in an As commercialization provide that next our plans will continue continue BRIUMVI, to expand additional step growth supply. MS to believe our about this support think and our is for efforts of the drug important we future security and

commitment MS. their of thank our want I and work hard for to people with to closing, all living TGers In

and is excited about efforts, is multiple new in to a a innovative MS TG therapies sclerosis. poised leader market, and the path to delivering for efforts, testament progress Through the forward. on become collective Our I'm our developing your focused

call Commercialization the to in detail. our hand I'll that, our commercial you walk Officer, Thank Adam, to through more over Adam go Chief Waldman, you. performance ahead. With

Adam Waldman

with future Mike. drive BRIUMVI steps and growth. revenue long-term you, we to launch, has marking share QX Thank quarter success its growth. the Yes. we've I'm strong excited are continued consistently BRIUMVI of taking our the another commercial expectations, to experienced exceeded with sequential Since

tend mentioned, the we third the same during BRIUMVI over in slow, growth where million, a $XX.X as quarter into saw hub of growth fastest-growing in And where particularly we from while dynamics U.S. Mike enrollments approximately achieved sales XX% MS last net quarter that August, year, As record to and quarter-over-quarter XXX% the visits enrollment DMT summer October second September, expected quarter market. the and we continued reflecting some solidifying did rebounded our new and into in month. July momentum patient observe

We MS launch. the new for XX% QX in approximately segment prescribers overall treatment the and continue X,XXX setting, growth since of steady including the from across Encouragingly, to in accounts X/X prescribers of approximately XXX of came centers, and which our our is reaching prescribers nearly hospital new centers, fastest-growing top centers now XX% see XXX now business.

which We and convenient X yet its safety option. continue effective to including high strongly looking months. infusion believe best-in-class resonate a every profile, we level believe for BRIUMVI care with providers well-established in attributes a efficacy, treatment of X-hour health highly profile

Conference response the We excited BRIUMVI positive are September. to to see in particularly at the ACTRIMS overwhelming

health care MS and featured data in was As we garnered clinical leaders presented strong from and prominently, community. Mike the interest BRIUMVI the thought mentioned, providers

commercial from Several the perspective. a key takeaways emerged from conference

a we infusion, XX-minute which a the potential showed rapid could trial, profile. have the to represent believe significant our First, ENHANCE enhancement BRIUMVI for to

ENHANCE easier be potentially therapy. open-label patients with requiring reinforcing long-term the CDXX a for the the may potential many potential presentation We make BRIUMVI extension switching BRIUMVI's loading to showed efficacy and current satisfied underscored Second, without CDXX a from profile. safety, to this switch believe trial And will who best-in-class not dose. their its finally,

in and who have established confidence particularly reinforces new safety annualized the for this received to certainly seek resonate patients impressive The rate proposition data. our years, strengthened positioning long-term along X.XX visibility BRIUMVI XX at an relapse and anti-CDXX as therapies. therapy physicians of X at with demonstrated patient recognition of ECTRIMS its adopting value before and data BRIUMVI's believe MS. relapse will X-year X data consistent equivalent long-term preferred forms information relapsing years, The just with We in

success factor is infrastructure. contributing Another BRIUMVI's commercial of growing expansion the our of

field increase expansion we market. MS allowed rising presence have our U.S. BRIUMVI treatment nearly reach centers. demand across the that team, has for us support the our to our X This years, doubled last increase the and Over commercial ensuring can within adequately we key

more As physicians to been able we've a on engage educate BRIUMVI and profile. product the result,

investments treatment patients that campaigns awareness. awareness informed to on campaigns often Alongside forms at that commercial targeted accelerate relapsing BRIUMVI's are team directly among in These benefit expansion, BRIUMVI. of the empowering aimed benefits patients, Recognizing awareness of living decisions, have we in discussions believe by providers. our key patients at unique with patients more also health are MS that from the informed can launched with have patient started raising educating profile. have aimed we individuals can ensure increase We care their adoption and we to further drivers

as strategy patient-centric point focal activities continue and increase these we in plan in significantly remain investment will efforts beyond. expanding Our XXXX our and outreach a we XXXX, to in

and launch, ensuring significant made access. availability in strides Since BRIUMVI's we've

always XX% regional pleased that national are this we us, I has maintained payers. a As previously, and been we and with area for mentioned prioritized coverage

and process BRIUMVI. reimbursement Additionally, is our the doing patients sure exceptional make with patients can team customers access an and working facilitating job to

We and diligently our streamline have helped ensuring accessible the journey, which patient with worked to satisfaction. is adherence sustain minimal patient delay, has BRIUMVI that

our to infusion continues our time at expectations. continues to decrease and persistence to week exceed Our XX

the our very is Our organization commercial performance reinforces BRIUMVI's this capable of deliver to belief profile market, results. quarter and our continues to resonate that in continuing

we net million U.S. sales beyond, continued to to our expect are we we guidance million. As raising QX to and see $XXX $XXX look BRIUMVI full and year to growth, accordingly, for

to continue expectations our early this $XXX have year XXXX. from in million original million number exceed to provided $XXX guidance We raised our substantially and of full

excited ahead. be to continue We lies what about

strong. Our foundation is

positioned a are to quarters. into to well And We brand. coming the we we more are capture growth are BRIUMVI grow -- in blockbuster we believe poised

motivated, need. in care work In team TG their confidence every to more are to we I positive patients want their contributing their dedication also those Their work we're our want living day hard with thank to thank for bring with for efforts conclusion, our experience work. will in providers do, have outstanding continue those I but the continue and our and in BRIUMVI Together, focused extremely families. and to to for We to health Therapeutics. organization. MS certainly BRIUMVI their and the and trust to outcomes improve to

With call our that, Power, turn to the CFO. Sean I'll over

Sean Power

everyone to which results, be financial morning, for our & quarter you, section us. XXXX we Earlier website. our Adam, this detailed Media of third Thank on the joining again thanks and reported Investors viewed can

QX revenue. This morning, by highlighting our I'll start

bringing to As revenue year-to-date X-month for pleased are report Adam product quarter net million period, BRIUMVI BRIUMVI earlier, product revenue million. $XX.X to third detailed of the $XXX.X we our X-month net

Turning income period. our to statement the for now

in income September We report periods and generated are X XXXX. to pleased that X-month net we both the ending

approximately income $XX.X approximately excluding for For the X-month was or the per income September net months our XX, GAAP period million. X ended XXXX, net diluted $X.X was items, million noncash share. $X.XX When

Our OpEx approximately during million. at came guided low the our end quarter, $XX excluding in at the items, range noncash of

full X And months approximately expect for guidance for the the is to million. our $XXX well approximately come $XXX of we OpEx the OpEx below of XXXX in first Our million. year,

close I'll commercialization, with on provides equivalents position. the investment and our approximately us by our our million which future. in finally, We And a $XXX support the foreseeable cash ended continued for research securities, position efforts with briefly and third BRIUMVI strong touching financial business believe development the we cash cash, operations and to quarter

future. quarter. On a to approach and the shares with program, began we commenced slowly repurchase will related on the foreseeable a share continue I'd buying We note, back touch the third briefly like our third which during during for quarter measured

to the into the continue amounts Although during repurchased minimal, this the the year and third do we were program of remainder XXXX. throughout quarter share expect

over will I to the operator the begin turn that, to back call conference With the Q&A. now

Operator

Our today H.C. Instructions] Ed Wainwright. from first coming is from question White [Operator

Edward White

wanted I question. picture a ask First, big to

mentioned continued IV anti-CDXX versus thoughts BRIUMVI I on wanted release to in You in to subcu. and share MS of in just also for XXXX market that size you only in market press on growth expect the the but the not your see your thoughts XXXX. get

Michael Weiss

take Ed, a the Adam, Thanks, to do question. for at one? want that you crack

Adam Waldman

Sure, Ed.

picture, to see of low dynamic the to XX%. continuing mid-XXs can't mean, big grow. to to in I see grow even It's XX% share CDXX We no that today. that, reason continue So we

momentum think behind I class. the continues the

think we're a market of growth, lot the our we we to room and CDXX today, grow. have as far of As XX% share market about

Edward White

U.S.-based a And announced just manufacturing. question Okay. secondary on FUJIFILM the

gross have impact this any quarter-over-quarter. Will year margins pretty gross margin Your been this forward? consistent agreement have on going

Michael Weiss

Sean, you that? want tackle to

Sean Power

the In upfront think the term, We'll consistent. question. we the that in course And through remain associated run of with would that, have near some not. term, for gross thanks will absolutely long Ed, margins R&D. but expenditures

your short a question So answer gross no, margin. no real is, to impact on

Adam Waldman

and your still forgot the it's question we believe clear as one answer his -- part Mike said And is, to subcu. around in do of continuing. remarks, we IV patient I see to subcu Ed, the We preference it Yes. today. to XX% in that IV which terms was believe

Edward White

Congratulations the on quarter.

Michael Weiss

Thanks, Ed.

Operator

from question Evercore is DiFiore Next coming from ISI. Michael

Michael DiFiore

many count your I patient Congrats on for print quarter. XQ? And Were what And in wasn't channel dynamics separately, have received Two in during TRx scripts the inventory any me. this XQ? there the that how script was in hub? morning. noticed new been included the

Michael Weiss

for the Thanks tackle Adam, you the Sure. question. to want those, inventory and TRx?

Adam Waldman

Yes.

at no First are providing inventory All move to in from away changes question, Michael, in number. And there's the quarter. as inventory levels. the going that normal as far we're distributors enrollments,

use just grow down our as to in rate we -- of hospital think terms less likely the continue because go capture business, I to continues hospitals are to our -- hub. our

to forward. just we that going going So don't this accurate think is be measure an

garner that to hospitals can and it using are over directionally, sort think focus certainly. way it's of more fluctuating going it. I continue of or a not the we've capture more growing, as past quarters to more using just just think forward. the I we're help several rate we've whether play and into with not in it But guidance to sort we'll certainly revenue the and coming done on do as growing decided

the don't just think we was hub it good -- in enrollments beginning. are But

coming it good the higher use a private a where beginning our in more that much certainly hub I percentage from measure. think we of much was business had the practices consistently,

likely use interpreting of our data. of some coming creates then continue growing is the I hospitals, we to to business And just hub. more our less out remarks, fastest our said go -- information XX% it's that our segment, from difficulty as the about and enrollment of in out in As the here, now hub

Operator

coming Next question from Joseph Eric is from JPMorgan.

Eric Joseph

mentioned more a plan a might the infusion Just ENHANCE at on to Can coming picking what of you I up little randomized for a faster out assess either or what a per part for Would than need there as trial switch needing elaborate the a be be for that? time, infusion you as safety? indication infusion the And more You to to get data. shorter bit adopt of patient on label you a needed dose update exclusively -- patients? to of that sort ECTRIMS. support on of part would possibly loading just skipping -- like focus X

Michael Weiss

Yes. Thanks for the question, Eric.

primarily X don't infusion today. the so. study. unclear to your But patients safety. more infusion, need of is than need answer we to And more will than So the X I tell it's yes, last don't think I think for a on we'll probably the part safety question,

faster For looking And they do safety are with before when require other tolerability. you randomized they've been done companies they infusions, and -- historically, and usually trials. at

expectations that's I -- what are. think our we're

Eric Joseph

could, you how And bit follow-up, maybe kind a addition pivotal tracking a forward are about you the move what Okay. long to subcu or of talk in respect Great. verify if of sort little study? to safety with to a ultimately Can interval dosing I assess within initiative. sort of you a could of

Michael Weiss

Yes.

So subcu, we're looking again at bioequivalence. primarily with the

So tolerability PK. will again, material amount the the to And it's that just match the determine required materials. the of of yes,

too put site. tolerability in some to at a the in, would start see you injection much deterioration at point you If

how much how that impact you and But the primary material will to load That the tell bioavailability. the it mentioned, is as focus ultimately, you will tolerable you into injection, is. need

of year. to soon. said, data basically are come pieces We're come X that hoping, next all able that together to will those pieces early have point like those some together. it's share But I So at -- . be to

Eric Joseph

cell Are you a looking at decline? component? B PD a Is there of sort

Michael Weiss

issue level. share Yes. is any in decline that real with B-cell you dose I not an could

Operator

from next Tara is Cowen. TD Your Bancroft from question coming

Tara Bancroft

-- similar just saw seasonal you guidance, be growth out guess, ahead and a year of on sequential the steady QX. just heavy -- I a like it would you from a your looking on QX we over or year But this and near-term helpful. growth, growth assumes incrementally really here about last assume cadence thinking impacts? like this with higher than like or was and now, envision should that's I dynamics bit here how XXXX under in wondering, with Just XX% from XX% So

Michael Weiss

do you Sure. Thanks. little? Adam, to a talk want

Adam Waldman

to we mean, information Sure. question, Yes. Tara. best when provide for try it. we the the Thanks we I have have

guidance do some trajectory growth. sequential as think and of continue here this and strong to and things revenue some in to the that We're fuel I mentioned is patient of and remarks things, continuing I awareness hoping shows other growth product. will the we are make the investments around my

we this As to and I make mentioned, brand blockbuster think a we're poised trajectory. that

think if the in are general, in there are seasonal MS dynamics look you season -- that I at some there are market quarterly play.

in affect BRIUMVI. we some the very that things We're think mentioned, I traction, future summer are is that to the I months about are just market excited QX, the were But getting exact and in the doing for As poised what line. there more. we're can in grow

Tara Bancroft

volume interval Okay. understand expectations just a there, Great. what previous of But with you helpful. targeting was And I quick tell follow-up ideally us a you're about subcu. and the lot perhaps the can formulation? subcu dosing question that mentioned you which on

Michael Weiss

Sure. Yes.

mean, frequently I as ideally it a would possible. So be less

month But think, we frequently I and no profile, we'll than that, be every other working be that's bar minimum And bar other think, would -- minimum I promises. that, even of target fantastic, be the sort we're that. minimum that think is less course. for a month, obviously would every the towards the be would certainly But I yes, think is of targeting.

Operator

coming is Matt today from Thalmann. question Ladenburg next Kaplan from Your

Matthew Kaplan

rates seeing on I guess Adam, for on you're expand in you other results. quarterly Congrats space? how to can and of the persistence therapies it compares the the

Adam Waldman

but that benchmark and the CDXX for question. -- doing good, or we're it we're are so expecting. if week XX like thanks -- IV are our what's And that doing it numbers not and only we other with better, competitor. looks compliance and at -- Matt, the sort Yes, We there to the we're published. we looks And that see collect what the like that's we than of been least we're on compliance as data, published -- out continuing continue again, have

Matthew Kaplan

clinical just the that the Okay. you could you incorporated could a practice. Great. have the studies ENHANCE necessary label? you to follow-up complete do when on When questions see the think data to available with and on And respect update that into

Michael Weiss

Yes. Thanks, Matt.

sometime It's would So the enrollment. least going take, enrollment. XXX or subjects. studies, be of It's Those be should goal got take year give year started short. again, a reasonable XXX so. to next to randomized to studies or Follow-up size. get those of a a It's, with trial at year. We've

and So a we data pretty put patients should be get able to and get follow the filing. that quickly together

so in And probably it's you to X-year think into case to I even a get process best X- scenario, the we're -- label.

Operator

coming Mayank Riley is from B. Next Mamtani question today from Securities.

Mayank Mamtani

Team, congrats on a strong quarter.

on maintenance if juncture So and split, able over BRIUMVI share are BRIUMVI to BRIUMVI patients? the new confirm you able patients, what you to at to takes of new the to maybe between patients and revenue the maintenance if are

you the versus on comment percent grabs? the perspective are to diagnosed on seeing up switch, for patients? any color share patients And any that. to class in hear love within RMS marketplace what on the -- newly Would CDXX by did would to on new hear intra-CDXX And for chance love any you set

Michael Weiss

Sure. Adam, ]? want crack to Thanks, [ do Mayank. you

Adam Waldman

Yes.

for coming XX lion's next so back quarters we the we do As down, get the and in in continue couple prescriptions share will the turn and that -- several versus question, the start we effect going so far that, upside as But right? first new on to mostly the continue and the infusions of week expect as quarters forth. is stacking repeat. split patients to still be to next stack revenue will of Repeat the

and a -- -- question second perspective. several to that's the of -- The newly right, But is majority. I Mayank? was become today, share of think the but dominant diagnosed, next still the news in it's amount revenue increase that So from repeat quarters, we split the expect do

Mayank Mamtani

accurate. a That's Yes.

Adam Waldman

Yes.

newly shares provided haven't We or new to in CDXX. diagnosed

see We question -- sizable KESIMPTA, And both from has your we switching. haven't from continue we provided those shares. and steady And third to and a launch. our pretty coming that of about consistent OCREVUS remained BRIUMVI and was business then portion do since see switches

Mayank Mamtani

Are on indicated of that of very might between to to one supply you be comment the the in the the then have XX% surveys facilities? hence on implication. recent patients long-term you up Because be able any may grabs, our up for and that U.S. lastly, And manufacturing so Korea Yes. Mike. mind biologics goal quantify expansion Any way would to helpful, question.

Michael Weiss

Yes.

what don't FUJI. So required Diosynth, securing for a I obviously, a think what of moment, good we But this is at and both have long-term between supply Mayank. for Samsung we answer think we're you is

Operator

is Corinne from Goldman Sachs. coming from question Next Johnson

Corinne Jenkins

Maybe a us. couple from

source there think the of and the do bulk care guess, MS coming why of patient a been are in new growth patients You taken you a remind your talked growth of you. portion about from that's good patients hospital of I us for setting. such

steady an patient And get well even accelerating year my as X into basis of see is, the second or you we maybe kind here? then about launch as could you XXXX, like new think absolute into growth question on

Michael Weiss

more new BRIUMVI. that patients more second kind with always on that We've certainly Yes, BRIUMVI, believe will go question. we as Sure. accelerating go we of XXXXX. get I'll start the speaking, into starts the we're mean, on felt patients do just that patient generally I

that it with inflection that have people the definitely when you and So point comes an of have mass. on critical sort there's enough

think So we part that's it. of

may remarks, the size whenever we expanded how point many to As get expanding our We're inflection of Adam in to marketing prepared into we taking XXXX. are our can push to mentioned coming hard and his as We've that that team. patients steps efforts be. commercial as

I mean, yes, is think Obviously, we've had that is the it to XX% thus far quarter-over-quarter promise don't So it. can't problematic. possible? XX% growth steady mean, I I I

of But get a it will within think that into as possible us also pretty it's blockbuster amount could short darn I the yes, to time. to XXXX. think good continue accelerate I rate we growth a bring is and

and you one the business do about comes take hospitals? want of Adam, percentage from the to hospital the setting that

Adam Waldman

yes. Yes,

prepared XX% that And it's patients my hospital we the -- where the in segment, of why segment the in now today And we're it of to hospital having That's XX% it probably the setting. majority remarks. continued is is treated. Corinne, as expansion being the So into I think are are mentioned is patients seen fastest-growing encouraging. U.S. in being

Operator

Our question Fitzgerald. Prakhar from next coming is Agrawal today from Cantor

Prakhar Agrawal

share even the has seeing that on Congrats it's where now in quarter. ground subcu Maybe you what terms the gaining on are of OCREVUS launched, firstly, more from, qualitatively?

you've And there priorities, years. second question, front? share the the a the allocation buyback the explore on allocation broader Or next few expand on other over to started any Maybe generating can obviously lot cash of program? capital plans capital is any mechanisms you

Michael Weiss

to competitive market what in want we've dynamics you in Adam, about the Thanks, Sure. recently? seen talk Prakhar. do

Adam Waldman

Yes. Sure.

best thanks remarks, to no So had October. prepared in the ever Prakhar, date. mentioned the seen we We as enrollments -- OCREVUS in impact question. I of month We've the novo from for de had

as can now. right impact as no we tell So far

Michael Weiss

off cash, yes, been to that started well, continuing It is of allocation -- we we've with ongoing mention of share terms in that did something conservatively on program. buyback Prakhar, Sean And we're an committed the basis.

we allocating more over share believe cash yes, do time we'll buybacks. to So be

remarks committed to of in prior as Adam in alluded BRIUMVI. But answer, the use again to and prepared in we're expanding I his as addition, the

by modest grow be grow a get we build we're think our to as the we'll marketing closely, and and pretty budget. when to launched which, out followed cash pretty build toward budget I team, have marketing obviously, in a continuing has to marketing going everyone with our And efforts So knows continuing to us 'XX. healthy time allocating 'XX, we we started

and think to So we're blockbuster leaning to get the as brand, going make quickly as We try we're BRIUMVI there we opportunity. can. again, we as I sure into see a

likely more to trials the So of be XXXX right? faster in about and obviously programs to clinical front skipping commencing of that and, you be running course, the these grouping. infusions, we several cash as investing of And will be we'll the using those again, earlier, streamline subcu, going So that that investing in heard we're doses activities. than in end which the priorities not is randomized of for highest part

going well. those in investments we're to So make as

really excess moving that going well. where the we're mentioned, excited make some to And eyes program we doing, is forward goes. development augments we're And azer-cel is our we peeled we're Obviously, our something active. there. cash potential the then if as think and that's what about we see are as investments So there and and business lastly, of complements

I think we're in how of as potential end on about cash, not blockbuster quickly gets So BRIUMVI got making possible gets we've excess the the say, that with spent for as level. front sure the uses to plenty I'd investments it except, dogmatic although

Operator

question is Roger Jefferies. from Song coming from Next

Jiale Song

related BRIUMVI then Congrats follow-up allocation questions just maybe the on quarter. pipeline. a additional for Most the of been for capital my to those had answered. And

of concept then able provide in indication, support some start be trial Number to data BRIUMVI is us So -- you this give one the year later one. to non-MS proof terms plan? and the expanding of to when would you the

Do terms and next therapy. then will in is expect the what of update of patients data? maturity allogeneic to number some the data you us the to in cell data the year? share principle two give Number be terms the And of of then the

Michael Weiss

Yes. Thanks, Roger.

look, year. since study hopeful we're Yes, question, it's work to get backwards the the So I fresh I'll then mean, this started I'll question. start later second that

these determined. logistics I early X got to quickly working patient our the we've it put same not, yet be on as data out think, next patients we left that on not We'll first If year. in. to of months rapidly some put of coming The with cadence and will be is other is trial, the It's the trials ability as of to patients can. hopefully get as biologics. So

get -- So year. we patients we as number of as a can can, but can data quickly if decent get some on sometime next out hopefully we

have hard enrolled although, slowly. and any it's until the available wouldn't historically really half data can we studies more that, likely these fast anticipate But I again, second But year. of enroll, again second than to tell how half the

study, which to that. has and lot in that MS a of areas promise slated let's eye into. we So do some a hopeful the we other intend keep in that areas progressive Because I look think on it have particularly to

So that We'll you keep TBD on posted. one, Roger.

the MS could BRIUMVI that, of the outside we our beginning year, was that interest say probably of plans, terms did in note from I of And priorities. the the lowest and near-term

some I that and getting end when on and non-MS on patients report the if think of we this we it indications still, working are year can happens. toward before

evaluating cell And but subcu look options other our and decide. of an our I I to options. been also this you move indications. us said it's as whether these some new at gives or before, we've all think so really And the potentially right new challenge taking of more in it's areas know the opportunity with IV data information, thought really plans into that disease time. opportunity I the of mean, of out that's MS much the and are now CDXX B across been we've part there's outside come multiple

I'm have to into XXXX, trials to certainly non-MS be. this working any putting discuss I to best going team on that us is indications screen. are the helping we'll assuming the and is about definitely today, next that more So The get up and patients is year, we'll And running. and talk evaluate what on but radar commercial the team it don't specifics

Operator

or session. over the our I'd We turn to reached of . back the comments. floor end closing for any question-and-answer like further

Michael Weiss

look expansion the call. today, effort, commercial to for our BRIUMVI We spend expanding in pipeline. and footprint BRIUMVI; our our next, Phase X advancing including as launch for MS finally, commencing progressive the BRIUMVI be at marketing; today's development, key well positive through out And we'll enhanced increasing priorities, our into you. opportunities several into continue our as subcutaneous switch our year. And Thank new azer-cel everyone, indications to first, in initiatives next again, study and discussed the focused in exploring on end continuing building looking thanks expand Great. our and as us of on to our year forward joining momentum

close providers making once health for and who and shareholders happen. and for to loyal all by with like Have day. whole in MS again, their team I'd trust their BRIUMVI the great and a support it those that, put With thanking our TG care their

Operator

webcast. today's conclude That you. teleconference does Thank

your you time, today. may day. You We for have disconnect participation and your line this at thank a wonderful

TG Therapeutics (TGTX) 4 Nov 242024 Q3 Earnings call transcript